Stock News

The designations cover a colorectal cancer combination and lung cancer monotherapy, both based mainly on a first-in-human study.

The Oct. 16 proposal seeks approval for up to 435,859,500 shares, with control passing to Metaplanet Holdings if the deal closes.

Shares priced at 1.5 pence represent about 15 per cent of enlarged capital, with London admission expected around Oct. 15.

The 220-person ZUPREME-2 trial also showed improved HbA1c; Zealand says the first participants have begun treatment in its Phase 3a program.

Four holes are the first results from a planned 12,000-metre Kwanika program; the project's preliminary economic assessment is delayed.

The DSB-96 step-out is 70 metres south of an earlier hole; Eloro aims to finish the initial 10,000 metres by year-end.

The biopsy measure improved against placebo after a gluten challenge, with p=0.0176; argenx plans Phase 3 development.

The voucher came with Genglycos approval; payment awaits an antitrust waiting period and other closing conditions.

A second AG infill hole returned 37.2m at 177.7 g/t silver equivalent, while lower elevation drilling continues.

The Oct. 7 results show 250 MW live at Polaris Forge 1 after quarter end, while the 210 MW Delta Forge 2 lease dates to June.

Hole CS26-096 also cut 101.6 metres at 1.02 per cent lithium oxide entirely outside the conceptual pit shell used in April's resource estimate.

Scout says Oracle's VPPA covers a majority of the output from its operating 300 MW Ranchero farm; contracted megawatts, price and start date were not disclosed.

Trulieve's Oct. 7 release says notes secured by its Jefferson County cultivation site were repaid, leaving about US$225M of debt.

The ALPHA-02 deal is expected to add US$24 million a year, but the buyer and deployment date are undisclosed.

Preliminary results of Rock Tech's ongoing definitive feasibility study use a Red Rock design capacity of about 30,000 tonnes of lithium salts a year.

Séguéla needs 42,557 gold ounces in Q4 to hit its low-end annual target as Fortuna budgets US$109M for a plant expansion.

Sasa lead output rose 21 per cent in the third quarter as higher head grades lifted production at the North Macedonia mine.

The 510(k) decision covers resting ECG use in adults and children, but HeartSciences has set no device launch date.

Finland's environmental agency asked developer Tuike Finland to suspend land-altering preparation at Muhos and Kajaani by Oct. 23.

Nine-month test deliveries more than doubled, while third-quarter CyPath revenue awaits formal results.

Vaxcyte expects both underwritten offerings to close Oct. 9, adding funds for adult vaccine trials and manufacturing ahead of a planned U.S. filing.

Auric paid A$6.5 million cash at settlement; A$3 million in shares awaits a vote, with up to A$7 million more tied to resource milestones.

PharmaLogic supplied doses to hospitals in Indiana and Ohio; Telix's Oct. 6 launch release gave no Pixclara sales target.

The Oct. 5 placement issued 4.84 million shares at US$1.16 each and gave the placement agent warrants for another 387,464 shares.

Fiscal fourth-quarter revenue rose 68 per cent to US$567 million, with integrated memory supplying most of the dollar increase.

The live application separates medical marijuana manufacturers, distributors and labs; state licences remain a condition of registration.

The Oct. 5 rule caps adult-use edibles at 10 milligrams per serving and 100 milligrams per package; medical edibles have higher caps.

An Oct. 6 SEC amendment identifies a SEDAR+ notice changing the bid's consideration and expiry after Curaleaf announced new cash and share terms.

The Oct. 1 cash subscription issued 926,784 WISeSat shares at US$10.79; a November price test could add up to 1,073,216 shares.

The primary IPI 3 to 5 cohort showed a 0.49 hazard ratio, while the partners plan regulatory talks without a stated filing date.

Blaize estimates Q3 revenue at US$0.5M and expects the remaining NeoTensr receivable to be paid in Q4.

Initial power availability is expected in 2028; the release names no tenant, power provider or construction budget.

The study will test tablets after 21 weeks of injections in about 195 adults, with weight change tracked through week 33.

Quantum said on Oct. 6 it had entered a Study Start-Up Agreement; it gave no first-dose or readout date.

Orexo expects to announce final issue terms preliminarily on Nov. 3 and plans a shareholder vote for Nov. 6.

International Resources Holdings must state whether it intends to bid by 5 p.m. GMT on Nov. 17 under Irish takeover rules.

Agency feedback follows a Phase 3 miss in congenital hyperinsulinism; Rezolute will weigh its filing strategy after tumor HI data.

The New Zealand explorer reports a 3.6-metre true width and aims to update Auld Creek's resource estimate in the fourth quarter.

The 8.5 per cent property loan matures in April 2034 and puts cultivation sites in Johnstown and Palatka behind the debt.

Strive reported 13,498,082 SATA shares on Oct. 2, up 1,304,902 in a week; the indicated dividend rate can change.